Home> Products> glucose dependent manner

{ "products": [ { "_id": "68b02393f5434d48fca8b8ca", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "TRELAQWK 50", "description": "TRELAQWK 50 is a modern oral antidiabetic tablet containing Trelagliptin 50 mg, specially developed for adults with type 2 diabetes mellitus. This once-weekly medication helps regulate blood sugar effectively, offering both convenience and strong clinical outcomes. With its advanced formulation, TRELAQWK 50 supports better glycemic control, making it easier for patients to lead a balanced and healthier lifestyle.\nManufactured under strict quality standards, TRELAQWK 50 ensures patient compliance, long-term safety, and efficacy in diabetes management.\nKey Ingredient\nTrelagliptin (50 mg):\nA unique, long-acting DPP-4 (dipeptidyl peptidase-4) inhibitor that allows weekly dosing, ensuring higher treatment adherence while maintaining effective control over blood glucose levels.\nKey Benefits of TRELAQWK 50\nProvides consistent blood sugar management with just one tablet per week\nEnhances insulin secretion while lowering glucagon levels in a glucose-dependent manner\nHelps reduce both fasting and postprandial blood glucose\nConvenient choice for patients with busy schedules who struggle with daily tablets\nLow risk of hypoglycemia when used as monotherapy\nSupports long-term improvement in HbA1c levels\nMechanism of Action – How TRELAQWK 50 Works\nTRELAQWK 50 works by blocking the DPP-4 enzyme, which normally degrades incretin hormones such as GLP-1 and GIP. These incretins are vital for maintaining blood sugar balance. By prolonging incretin activity, trelagliptin:\nStimulates insulin secretion from the pancreas\nReduces glucagon release from alpha cells\nHelps lower blood sugar, particularly after meals\nThis mechanism provides both effective glycemic control and improved patient compliance.\nDirections for Use\nTake one tablet of TRELAQWK 50 once a week, on the same day each week\nCan be taken with or without food\nSwallow whole with a glass of water\nFollow your doctor’s advice for dosage adjustment\nDo not double the dose if missed; consult your healthcare provider\nPossible Side Effects\nTRELAQWK 50 is usually well-tolerated. However, some patients may experience:\nMild headache\nNasopharyngitis (cold-like symptoms)\nDiarrhea\nStomach discomfort or indigestion\nRare allergic reactions (rash, itching)\nIf any unusual or persistent side effects occur, seek medical advice promptly.", "price": 375.0, "discountamount": 112.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": null, "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2165, "imageuri": "https://productimages.withfloats.com/actual/68b023971624ba892ffd8c69.png", "tileimageuri": "https://productimages.withfloats.com/tile/68b023971624ba892ffd8c69.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2025-08-28T09:38:27.036Z", "updatedon": "2025-08-28T09:38:27.036Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/trelaqwk-50/2165", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "trelagliptin 50 mg", "category": "DIABETIC RANGE", "tags": [], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "6842b74dc10e9000933fa1d7", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "TRELAQWK 50", "description": "TRELAQWK 50 is a modern, once-a-week oral antidiabetic medication containing Trelagliptin 50mg, developed to support adults with type 2 diabetes mellitus (T2DM). This formulation is designed to improve blood glucose regulation while offering patients the convenience of weekly dosing. Created under rigorous quality standards, TRELAQWK 50 combines therapeutic effectiveness with enhanced compliance and lifestyle ease.\n\nActive Ingredient:\nTrelagliptin 50mg\nA next-generation DPP-4 (Dipeptidyl Peptidase-4) inhibitor with an extended half-life, enabling once-weekly administration. It helps improve glycemic control by preserving incretin hormones that naturally support insulin secretion and reduce glucagon production.\n\nKey Advantages:\nDelivers long-lasting blood sugar control with just one tablet per week\n\nEnhances insulin production and decreases glucagon levels in a glucose-dependent manner\n\nEffectively lowers both fasting and post-meal blood sugar levels\n\nPerfect for patients who find daily medications challenging\n\nLowers the risk of hypoglycemia when not combined with insulin or sulfonylureas\n\nContributes to better HbA1c levels over continued use\n\nMechanism of Action:\nTRELAQWK 50 functions by inhibiting the DPP-4 enzyme, which degrades incretin hormones like GLP-1 (Glucagon-Like Peptide-1) and GIP (Glucose-Dependent Insulinotropic Polypeptide). By preventing their breakdown, Trelagliptin extends the action of these hormones, resulting in increased insulin release and reduced glucagon levels. This mechanism is particularly effective after meals, helping maintain optimal blood glucose levels throughout the week.\n\nUsage Instructions:\nTake one tablet weekly, ideally on the same day each week\n\nCan be taken with or without meals\n\nSwallow whole with water—do not crush or chew\n\nFollow your doctor's dosing guidelines exactly\n\nIf you miss a dose, do not take two tablets together; speak with your doctor for guidance\n\nPossible Side Effects:\nTRELAQWK 50 is usually well-tolerated. However, some individuals may notice:\n\nHeadache\n\nCommon cold-like symptoms (nasopharyngitis)\n\nMild diarrhea\n\nGastrointestinal discomfort\n\nRare allergic responses like skin rashes or itching\n\nShould any side effects persist or worsen, consult your healthcare provider immediately.", "price": 375.0, "discountamount": 112.5, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": [ "offering patients", "worsen consult", "skin rashes", "chew follow", "meals swallow", "dpp4 enzyme", "sulfonylureas contributes", "enhanced compliance", "support adults", "trelaqwk 50trelaqwk 50", "hormones resulting", "hba1c levels", "tablet weekly ideally", "week usage instructions", "increased insulin release", "reduced glucagon levels", "degrades incretin hormones", "decreases glucagon levels", "preserving incretin hormones", "healthcare provider immediately", "side effects persist", "doctors dosing guidelines", "breakdown trelagliptin extends", "glp1 glucagonlike peptide1", "weekly dosing created" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2131, "imageuri": "https://productimages.withfloats.com/actual/6842b764900dc96c430f8095.png", "tileimageuri": "https://productimages.withfloats.com/tile/6842b764900dc96c430f8095.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2025-06-06T09:39:25.819Z", "updatedon": "2025-08-28T11:15:31.153Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/trelaqwk-50/2131", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "trelagliptin 50 mg", "category": "DIABETIC RANGE", "tags": [ "Trelagliptin in India", "Trelagliptin brand name", "trelagliptin 50 mg", "trelagliptin 50mg", "trelagliptin 50mg", "trelagliptin 50mg" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "68134d097702eb2332e5ccb0", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "GLICLAGLAZE 40", "description": "GLICLAGLAZE 40 is an oral antidiabetic medication containing Gliclazide 40 mg, formulated to effectively manage Type 2 Diabetes Mellitus. It belongs to the class of drugs known as sulfonylureas, which are specifically designed to control blood glucose levels in adults who cannot manage diabetes through diet and exercise alone. By promoting insulin secretion and improving glycemic control, GLICLAGLAZE 40 helps prevent long-term complications associated with uncontrolled diabetes, such as nerve damage, kidney issues, and cardiovascular diseases.\n\nKey Ingredient\nGliclazide (40 mg):\nGliclazide is a second-generation sulfonylurea, known for its dual effect: stimulating insulin release from the pancreas and offering antioxidant properties. It not only lowers blood sugar but also provides vascular protection, making it suitable for patients at risk of cardiovascular events.\n\nKey Benefits\nEffectively reduces high blood sugar levels in Type 2 diabetes\n\nStimulates natural insulin secretion from pancreatic beta cells\n\nProvides cardiovascular protection by improving endothelial function\n\nMinimizes the risk of microvascular complications like retinopathy and nephropathy\n\nSuitable for long-term glycemic control when lifestyle measures are insufficient\n\nHelps maintain a stable glucose profile throughout the day\n\nHow Does It Work?\nGLICLAGLAZE 40 works by targeting the pancreas to enhance the secretion of insulin, which is essential for lowering blood glucose levels. Gliclazide binds to specific receptors on pancreatic beta cells, triggering the release of insulin in a glucose-dependent manner. This ensures that the medication works primarily when glucose levels are elevated, thus reducing the risk of hypoglycemia compared to older sulfonylureas. Additionally, its antioxidant properties contribute to improved vascular health, protecting blood vessels from oxidative damage often seen in diabetic patients.\n\nDirections for Use\nTake GLICLAGLAZE 40 exactly as prescribed by your healthcare provider\n\nUsually taken once or twice daily, preferably before meals\n\nSwallow the tablet whole with water — do not crush or chew\n\nMaintain a regular schedule for meals and medication to avoid hypoglycemia\n\nMonitor blood glucose levels regularly to track progress\n\nAlways combine with a balanced diet and exercise plan for optimal results\n\nSide Effects\nThough generally well-tolerated, GLICLAGLAZE 40 may cause some side effects:\n\nCommon Side Effects:\n\nHypoglycemia (low blood sugar)\n\nHeadache\n\nDizziness or light-headedness\n\nNausea or stomach discomfort\n\nWeight gain (in some patients)\n\nRare but Serious Side Effects:\n\nLiver enzyme abnormalities\n\nSkin rash or allergic reaction\n\nBlood disorders like anemia or thrombocytopenia\n\nVisual disturbances (usually temporary)\n\nSeek immediate medical attention if symptoms of severe hypoglycemia, such as confusion, fainting, or seizures, occur.", "price": 120.0, "discountamount": 34.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": [ "gliclaglaze 40", "exercise plan", "balanced diet", "meals swallow", "nephropathy suitable", "gliclaglaze 40gliclaglaze 40", "seizures occur", "confusion fainting", "severe hypoglycemia", "medical attention", "temporary seek", "patients rare", "lightheadedness nausea", "track progress", "regular schedule", "daily preferably", "healthcare provider", "oxidative damage", "hypoglycemia compared", "glucosedependent manner", "specific receptors", "lifestyle measures", "microvascular complications", "secondgeneration sulfonylurea", "uncontrolled diabetes", "manage diabetes", "specifically designed", "chew maintain", "glucose levels", "cardiovascular protection", "promoting insulin secretion", "diabetic patients directions", "older sulfonylureas additionally", "medication works primarily", "oral antidiabetic medication", "stable glucose profile", "insufficient helps maintain", "vascular protection making", "thrombocytopenia visual disturbances", "antioxidant properties contribute", "longterm glycemic control", "pancreatic beta cells", "lowers blood sugar", "offering antioxidant properties" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2099, "imageuri": "https://productimages.withfloats.com/actual/68134d0b4b698d44a8c316f4.png", "tileimageuri": "https://productimages.withfloats.com/tile/68134d0b4b698d44a8c316f4.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2025-05-01T10:29:29.141Z", "updatedon": "2025-05-01T10:29:29.141Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/gliclaglaze-40/2099", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "Gliclazide 40 mg", "category": "DIABETIC RANGE", "tags": [ "Gliclazide 40 mg uses in Hindi", "Gliclazide 40mg brands", "Gliclazide 40 mg price", "Gliclazide 40mg side effects" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "668e8611b9f7300708fe1240", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "TRIOGLIMITERIS 1/0.2 ", "description": "TRIOGLIMITERIS 1/0.2 \nVoglibose 0.2 mg, Glimepiride 1 mg & Metformin Hydrochloride 500 mg\nIntroduction\n\nTRIOGLIMITERIS 1/0.2 is a combination medication containing Voglibose, Glimepiride, and Metformin Hydrochloride. It is primarily used in the management of type 2 diabetes mellitus to improve glycemic control through different mechanisms of action targeting glucose metabolism.\n\nComposition\n\nVoglibose (0.2 mg): An alpha-glucosidase inhibitor that delays the digestion of carbohydrates in the intestine, thereby reducing postprandial blood glucose levels.\nGlimepiride (1 mg): A sulfonylurea derivative that stimulates insulin release from pancreatic beta cells, enhancing glucose uptake in peripheral tissues.\nMetformin Hydrochloride (500 mg): A biguanide that decreases hepatic glucose production, improves insulin sensitivity in peripheral tissues, and reduces intestinal glucose absorption.\nMechanism of Action\n\nTRIOGLIMITERIS 1/0.2 combines the actions of its components to achieve optimal glycemic control:\n\nVoglibose: Inhibits alpha-glucosidase enzymes in the intestine, delaying carbohydrate digestion and reducing the absorption of glucose after meals.\nGlimepiride: Stimulates insulin secretion from pancreatic beta cells in a glucose-dependent manner, thereby lowering blood glucose levels.\nMetformin Hydrochloride: Decreases hepatic glucose production through suppression of gluconeogenesis and enhances peripheral glucose uptake and utilization by improving insulin sensitivity.\nIndications\n\nTRIOGLIMITERIS 1/0.2 is indicated for:\n\nType 2 Diabetes Mellitus: Used to improve glycemic control in adults when diet, exercise, and monotherapy with metformin or sulfonylureas alone are not sufficient.\nDosage and Administration\n\nThe typical dosage of TRIOGLIMITERIS 1/0.2 is one tablet taken orally with meals, usually once or twice daily.\nDosage adjustments may be required based on individual patient response, blood glucose levels, and renal function.\nIt is essential to adhere to the prescribed dosage regimen to achieve optimal therapeutic outcomes.\nSide Effects\n\nCommon side effects of TRIOGLIMITERIS 1/0.2 may include:\n\nHypoglycemia (especially when used in combination with insulin or other antidiabetic medications)\nGastrointestinal disturbances (such as nausea, vomiting, diarrhea, or abdominal discomfort)\nWeight gain (mainly associated with sulfonylureas)\nMore severe side effects can include:\n\nAllergic reactions (rash, itching, swelling)\nLactic acidosis (rare but serious adverse effect associated with metformin use)\nHepatic dysfunction (monitor liver function tests periodically)\nPrecautions\n\nUse with caution in patients with renal impairment, hepatic dysfunction, or other significant medical conditions that may affect drug metabolism or excretion.\nRegular monitoring of blood glucose levels, renal function, and liver function is recommended during treatment with TRIOGLIMITERIS 1/0.2.\nAvoid use in patients with type 1 diabetes mellitus or diabetic ketoacidosis.\nDrug Interactions\n\nTRIOGLIMITERIS 1/0.2 may interact with other medications affecting blood glucose levels, such as insulin, other oral antidiabetic agents, or drugs that affect renal function or hepatic metabolism. Close monitoring and dose adjustments may be necessary.\nConclusion\n\nTRIOGLIMITERIS 1/0.2 provides a comprehensive approach to managing type 2 diabetes mellitus by combining Voglibose, Glimepiride, and Metformin Hydrochloride. This combination targets different aspects of glucose metabolism, enhancing insulin secretion, reducing hepatic glucose production, and delaying carbohydrate absorption in the intestine. Proper dosage, administration, and monitoring for side effects are essential to achieve and maintain optimal glycemic control in diabetic patients using TRIOGLIMITERIS 1/0.2. Consultation with a healthcare provider is recommended for personalized treatment plans and management of diabetes with this medication.\nFor further information: \nEMAIL: info@sterispharma.com / contact@sterispharma.com \n CALL/WHATSAPP: 7877551268, 7849827488 \n Order NOW\n", "price": 195.0, "discountamount": 58.5, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 7, "_keywords": [ "500 mg", "0.2 mg", "one tablet", "Weight gain", "Glimepiride 1", "metformin use", "Proper dosage", "Glimepiride (1", "dosage regimen", "typical dosage", "renal function", "insulin release", "drug metabolism", "Lactic acidosis", "Close monitoring", "dose adjustments", "renal impairment", "diabetic patients", "insulin secretion", "different aspects", "Drug Interactions", "other medications", "Regular monitoring", "Dosage adjustments", "Allergic reactions", "peripheral tissues", "hepatic metabolism", "glucose metabolism", "insulin sensitivity", "healthcare provider", "Hepatic dysfunction", "Common side effects", "abdominal discomfort", "different mechanisms", "liver function tests", "diabetic ketoacidosis", "pancreatic beta cells", "combination medication", "carbohydrate digestion", "comprehensive approach", "serious adverse effect", "Metformin Hydrochloride", "carbohydrate absorption", "sulfonylurea derivative", "glucose-dependent manner", "optimal glycemic control", "type 1 diabetes mellitus", "type 2 diabetes mellitus", "More severe side effects", "alpha-glucosidase enzymes", "peripheral glucose uptake", "hepatic glucose production", "alpha-glucosidase inhibitor", "individual patient response", "personalized treatment plans", "optimal therapeutic outcomes", "Gastrointestinal disturbances", "intestinal glucose absorption", "other antidiabetic medications", "other oral antidiabetic agents", "postprandial blood glucose levels", "other significant medical conditions" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 1939, "imageuri": "https://productimages.withfloats.com/actual/668e86143a68154e11e7d822.jpeg", "tileimageuri": "https://productimages.withfloats.com/tile/668e86143a68154e11e7d822.jpeg", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-07-10T13:01:05.875Z", "updatedon": "2024-07-10T13:01:05.875Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/trioglimiteris-1-0-2-/1939", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "TRIOGLIMITERIS 1/0.2 ", "category": "DIABETIC RANGE", "tags": [ "glimepiride 1mg+metformin 500mg+voglibose 0.2 mg", "Glimepiride 2mg Metformin 500mg Voglibose 0.2 mg b", "glimepiride 2mg+metformin 500mg+voglibose 0.2 mg", "voglibose glimepiride & metformin hydrochloride (s", "voglibose glimepiride + metformin hydrochloride us", "glimepiride 1mg+metformin 500mg+voglibose 0.3 mg", "glimepiride 2mg+metformin 500mg+voglibose 0.2 mg g", "" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "6662c81c7247ae19c482b3d9", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "VILDIABATE 100 ", "description": "VILDIABATE 100 \nVildagliptin (100mg)\nIntroduction to VILDIABATE 100\nVILDIABATE 100 is an oral medication designed for the management of type 2 diabetes mellitus. It contains Vildagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor. Vildagliptin helps regulate blood sugar levels by enhancing the body’s natural ability to produce insulin and control glucose production. This medication is used in conjunction with diet and exercise to improve glycemic control in adults with type 2 diabetes.\n\nKey Component and Mechanism of Action\nVildagliptin 100mg\nVildagliptin is a potent and selective DPP-4 inhibitor. It works by inhibiting the DPP-4 enzyme, which is responsible for breaking down incretin hormones such as GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic peptide). These incretin hormones play a crucial role in glucose metabolism:\n\nGLP-1: Stimulates insulin secretion from the pancreatic beta cells in a glucose-dependent manner, inhibits glucagon release, slows gastric emptying, and reduces appetite.\nGIP: Enhances insulin secretion post-meal, aiding in the regulation of blood glucose levels.\nBy increasing the levels of these incretin hormones, Vildagliptin helps to improve insulin secretion in response to meals and reduces the amount of glucose produced by the liver.\n\nBenefits of VILDIABATE 100\nEffective Blood Sugar Control\nPostprandial Glucose Control: VILDIABATE 100 helps manage postprandial (after-meal) blood sugar levels by enhancing the body's natural response to food intake.\nFasting Glucose Control: By reducing hepatic glucose production, it also helps lower fasting blood sugar levels.\nAdditional Health Benefits\nLow Risk of Hypoglycemia: Vildagliptin has a low risk of causing hypoglycemia (low blood sugar) because it enhances insulin secretion only when blood glucose levels are elevated.\nWeight Neutral: Vildagliptin is generally weight neutral, making it a favorable option for patients concerned about weight gain associated with other diabetes medications.\nHow to Use VILDIABATE 100\nDosage and Administration\nRecommended Dosage: The typical dosage of VILDIABATE 100 is one tablet taken once or twice daily, depending on individual needs and the healthcare provider's instructions.\nAdministration: Take the tablet with or without food. Swallow it whole with a glass of water.\nGuidelines for Optimal Use\nConsistent Use: For best results, take VILDIABATE 100 regularly at the same time each day as prescribed by your healthcare provider.\nMonitor Blood Sugar Levels: Regular monitoring of blood sugar levels is important to ensure the medication is effectively controlling your diabetes. Adjustments to your treatment plan may be necessary based on these readings.\nFor further information: \nEMAIL: info@sterispharma.com / contact@sterispharma.com \n CALL/WHATSAPP: 7877551268, 7849827488 \n Order Now\nhttps://www.sterisonline.com/product/vildiabate-100-133452", "price": 275.0, "discountamount": 82.5, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 7, "_keywords": [ "GIP", "diet", "body", "EMAIL", "Order", "meals", "water", "glass", "GLP-1", "liver", "adults", "Action", "amount", "option", "potent", "readings", "Low Risk", "appetite", "exercise", "patients", "same time", "Mechanism", "regulation", "VILDIABATE", "one tablet", "Guidelines", "management", "food intake", "weight gain", "Optimal Use", "information", "conjunction", "Adjustments", "Introduction", "Vildagliptin", "sterisonline", "best results", "crucial role", "DPP-4 enzyme", "Hypoglycemia", "instructions", "sterispharma", "Key Component", "CALL/WHATSAPP", "typical dosage", "Consistent Use", "Administration", "treatment plan", "Weight Neutral", "natural ability", "oral medication", "low blood sugar", "glucagon release", "DPP-4) inhibitor", "natural response", "glycemic control", "individual needs", "gastric emptying", "insulin secretion", "incretin hormones", "glucose metabolism", "Recommended Dosage", "Regular monitoring", "healthcare provider", "blood glucose levels", "pancreatic beta cells", "dipeptidyl peptidase-4", "Fasting Glucose Control", "meal) blood sugar levels", "type 2 diabetes mellitus", "glucose-dependent manner", "selective DPP-4 inhibitor", "Additional Health Benefits", "hepatic glucose production", "other diabetes medications", "Postprandial Glucose Control", "Effective Blood Sugar Control", "glucose-dependent insulinotropic peptide" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 1514, "imageuri": "https://productimages.withfloats.com/actual/667d3bc9c134db5b38ba8354.png", "tileimageuri": "https://productimages.withfloats.com/tile/667d3bc9c134db5b38ba8354.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-06-07T08:43:08.09Z", "updatedon": "2024-06-27T10:15:31.785Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/vildiabate-100-/1514", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "VILDIABATE 100 ", "category": "DIABETIC RANGE", "tags": [ "vildagliptin 100 mg uses", "", "vildagliptin 100 mg generic medicine", "vildagliptin 100 mg side effects", "", "vildagliptin sustained release tablets 100 mg", "vildagliptin 100 mg brands in india" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "6662c4c88ecffe165c354dc1", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "VILDIABATE PIO ", "description": "VILDIABATE PIO \nVildagliptin 50 mg & Pioglitazone Hydrochloride 15 mg\nIntroduction to VILDIABATE PIO\nVILDIABATE PIO is a combination medication designed for the effective management of type 2 diabetes mellitus. It contains two active ingredients: Vildagliptin 50mg and Pioglitazone Hydrochloride 15mg. This dual-action formula targets different aspects of glucose regulation, providing comprehensive blood sugar control. It is used alongside diet and exercise to improve glycemic control in adults with type 2 diabetes.\n\nKey Components and Their Mechanisms\nVildagliptin 50mg\nVildagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that works by:\n\nEnhancing Incretin Levels: Vildagliptin inhibits the DPP-4 enzyme, which degrades incretin hormones such as GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic peptide). These hormones increase insulin secretion and decrease glucagon release in a glucose-dependent manner.\nImproving Postprandial Glucose Control: By enhancing the action of incretin hormones, Vildagliptin helps regulate blood sugar levels after meals.\nPioglitazone Hydrochloride 15mg\nPioglitazone is a thiazolidinedione that improves insulin sensitivity in muscle and adipose (fat) tissues. It works by:\n\nIncreasing Insulin Sensitivity: Pioglitazone enhances the body's response to insulin, allowing for better glucose uptake and utilization by cells.\nReducing Hepatic Glucose Production: Pioglitazone decreases the amount of glucose produced by the liver, helping to lower fasting blood sugar levels.\nBenefits of VILDIABATE PIO\nComprehensive Blood Sugar Control\nFasting and Postprandial Glucose Management: The combination of Vildagliptin and Pioglitazone effectively manages both fasting and postprandial (after-meal) blood sugar levels.\nImproved Insulin Sensitivity and Secretion: Vildagliptin enhances insulin secretion in response to meals, while Pioglitazone improves insulin sensitivity in peripheral tissues.\nAdditional Health Benefits\nLow Risk of Hypoglycemia: Vildagliptin has a low risk of causing hypoglycemia (low blood sugar) because it enhances insulin secretion only when blood glucose levels are elevated.\nCardioprotective Effects: Pioglitazone may provide additional cardiovascular benefits, such as improving lipid profiles and reducing inflammation, which can be beneficial for patients with diabetes who are at risk of cardiovascular diseases.\nWeight Management: While Pioglitazone may cause some weight gain due to fluid retention, Vildagliptin is generally weight neutral, balancing the overall effect on body weight.\nDosage and Administration\nRecommended Dosage\nDosage: The typical dosage of VILDIABATE PIO is one tablet taken once daily, preferably with a meal to enhance absorption and reduce gastrointestinal side effects.\nAdministration: Swallow the tablet whole with a glass of water. Do not crush, chew, or split the tablet unless advised by your healthcare provider.\nGuidelines for Optimal Use\nConsistent Use: For best results, take VILDIABATE PIO regularly at the same time each day as prescribed by your healthcare provider.\nMonitor Blood Sugar Levels: Regular monitoring of blood sugar levels is essential to ensure the medication is effectively controlling your diabetes. Adjustments to your treatment plan may be necessary based on these readings.\nFor further information: \nEMAIL: info@sterispharma.com / contact@sterispharma.com \n CALL/WHATSAPP: 7877551268, 7849827488 \n Order Now\nhttps://www.sterisonline.com/product/vildiabate-pio-134257\n", "price": 295.0, "discountamount": 88.5, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 7, "_keywords": [ "GIP", "diet", "Order", "meals", "EMAIL", "cells", "liver", "water", "glass", "GLP-1", "amount", "muscle", "adults", "Fasting", "adipose", "patients", "Low Risk", "exercise", "readings", "response", "Enhancing", "same time", "one tablet", "Mechanisms", "Increasing", "Guidelines", "absorption", "utilization", "Optimal Use", "information", "body weight", "Adjustments", "weight gain", "DPP-4 enzyme", "inflammation", "Introduction", "Vildagliptin", "Hypoglycemia", "sterispharma", "best results", "fat) tissues", "sterisonline", "CALL/WHATSAPP", "Administration", "VILDIABATE PIO", "glucose uptake", "Key Components", "Consistent Use", "treatment plan", "overall effect", "lipid profiles", "typical dosage", "Incretin Levels", "low blood sugar", "fluid retention", "glycemic control", "glucagon release", "DPP-4) inhibitor", "Weight Management", "insulin secretion", "incretin hormones", "different aspects", "thiazolidinedione", "peripheral tissues", "glucose regulation", "Regular monitoring", "healthcare provider", "dual-action formula", "insulin sensitivity", "blood glucose levels", "effective management", "dipeptidyl peptidase-4", "two active ingredients", "combination medication", "cardiovascular diseases", "Cardioprotective Effects", "type 2 diabetes mellitus", "meal) blood sugar levels", "glucose-dependent manner", "Recommended Dosage Dosage", "Pioglitazone Hydrochloride", "Additional Health Benefits", "Hepatic Glucose Production", "gastrointestinal side effects", "Postprandial Glucose Management", "comprehensive blood sugar control", "additional cardiovascular benefits", "Improving Postprandial Glucose Control", "glucose-dependent insulinotropic peptide" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 1512, "imageuri": "https://productimages.withfloats.com/actual/667d3d8c5443982e2f655655.png", "tileimageuri": "https://productimages.withfloats.com/tile/667d3d8c5443982e2f655655.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-06-07T08:28:56.298Z", "updatedon": "2024-06-27T10:23:02.274Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/vildiabate-pio-/1512", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "VILDIABATE PIO ", "category": "DIABETIC RANGE", "tags": [ "vildagliptin metformin hydrochloride tablets uses", "vildagliptin + metformin + glimepiride combination", "vildagliptin 50 mg side effects", "vildagliptin and pioglitazone hydrochloride" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "6662b5587de2b5203089e01d", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "VILDIABATE M 850 ", "description": "VILDIABATE M 850 \nMetformin (850mg)SR, Vildagliptin (50mg)\nIntroduction to VILDIABATE M 850\nVILDIABATE M 850 is a combination medication designed to manage type 2 diabetes mellitus effectively. It combines Metformin Hydrochloride Sustained Release (SR) 850mg and Vildagliptin 50mg. This dual-action formulation targets different pathways involved in glucose regulation, providing comprehensive blood sugar control. It is used alongside diet and exercise to improve glycemic control in adults with type 2 diabetes.\n\nKey Components and Their Mechanisms\nMetformin SR 850mg\nMetformin is a biguanide that helps lower blood sugar levels through several mechanisms:\n\nReduces Hepatic Glucose Production: Metformin decreases the amount of glucose produced by the liver.\nImproves Insulin Sensitivity: It enhances the sensitivity of muscle cells to insulin, promoting better glucose uptake and utilization.\nDecreases Intestinal Absorption of Glucose: Metformin reduces the absorption of glucose from the gastrointestinal tract.\nThe sustained-release (SR) formulation ensures a gradual release of the medication, providing prolonged therapeutic effects and reducing the risk of gastrointestinal side effects.\n\nVildagliptin 50mg\nVildagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that works by:\n\nEnhancing Incretin Levels: Vildagliptin inhibits the DPP-4 enzyme, which degrades incretin hormones such as GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic peptide). These hormones increase insulin secretion and decrease glucagon release in a glucose-dependent manner.\nImproving Postprandial Glucose Control: By enhancing the action of incretin hormones, Vildagliptin helps regulate blood sugar levels after meals.\nBenefits of VILDIABATE M 850\nComprehensive Blood Sugar Control\nFasting and Postprandial Glucose Management: The combination of Metformin SR and Vildagliptin effectively manages both fasting and postprandial (after-meal) blood sugar levels.\nImproved Insulin Sensitivity and Secretion: Metformin improves insulin sensitivity, while Vildagliptin enhances insulin secretion in response to meals.\nExtended Release Formulation\nProlonged Effect: The sustained-release formulation of Metformin ensures a steady release of the medication, providing long-lasting blood sugar control and minimizing peaks and troughs in blood sugar levels.\nReduced Gastrointestinal Side Effects: The gradual release of Metformin helps reduce common gastrointestinal side effects associated with immediate-release formulations.\nAdditional Health Benefits\nLow Risk of Hypoglycemia: Vildagliptin has a low risk of causing hypoglycemia (low blood sugar) because it enhances insulin secretion only when blood glucose levels are elevated.\nWeight Neutral: This combination is generally weight-neutral, making it a suitable option for patients concerned about weight gain.\nDosage and Administration\nRecommended Dosage\nDosage: The typical dosage is one tablet taken once or twice daily, preferably with a meal to reduce gastrointestinal side effects.\nAdministration: Swallow the tablet whole with a glass of water. Do not crush, chew, or split the tablet unless advised by your healthcare provider.\nGuidelines for Optimal Use\nConsistent Use: For best results, take VILDIABATE M 850 regularly at the same time each day as prescribed by your healthcare provider.\nMonitor Blood Sugar Levels: Regular monitoring of blood sugar levels is essential to ensure the medication is effectively controlling your diabetes. Adjustments to your treatment plan may be necessary based on these readings.\nFor further information: \nEMAIL: info@sterispharma.com / contact@sterispharma.com \n CALL/WHATSAPP: 7877551268, 7849827488 \n Order Now\nhttps://www.sterisonline.com/product/vildiabate-m-850-133455", "price": 299.0, "discountamount": 89.7, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 7, "_keywords": [ "GIP", "diet", "Order", "EMAIL", "water", "glass", "liver", "GLP-1", "peaks", "meals", "adults", "amount", "option", "troughs", "Fasting", "exercise", "Low Risk", "patients", "readings", "response", "Enhancing", "same time", "biguanide", "Guidelines", "one tablet", "weight gain", "Optimal Use", "information", "Adjustments", "utilization", "Vildagliptin", "Metformin SR", "sterispharma", "Hypoglycemia", "Introduction", "best results", "sterisonline", "DPP-4 enzyme", "muscle cells", "CALL/WHATSAPP", "treatment plan", "glucose uptake", "steady release", "typical dosage", "Key Components", "Administration", "Weight Neutral", "Consistent Use", "low blood sugar", "Incretin Levels", "gradual release", "glycemic control", "VILDIABATE M 850", "glucagon release", "Prolonged Effect", "DPP-4) inhibitor", "incretin hormones", "insulin secretion", "glucose regulation", "several mechanisms", "different pathways", "Regular monitoring", "healthcare provider", "Insulin Sensitivity", "blood glucose levels", "Intestinal Absorption", "combination medication", "dipeptidyl peptidase-4", "gastrointestinal tract", "dual-action formulation", "meal) blood sugar levels", "type 2 diabetes mellitus", "glucose-dependent manner", "Recommended Dosage Dosage", "Additional Health Benefits", "Hepatic Glucose Production", "Extended Release Formulation", "sustained-release formulation", "prolonged therapeutic effects", "immediate-release formulations", "Postprandial Glucose Management", "long-lasting blood sugar control", "comprehensive blood sugar control", "sustained-release (SR) formulation", "common gastrointestinal side effects", "Reduced Gastrointestinal Side Effects", "Improving Postprandial Glucose Control", "glucose-dependent insulinotropic peptide", "Metformin Hydrochloride Sustained Release" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 1504, "imageuri": "https://productimages.withfloats.com/actual/667d44a2576e8da931df856b.png", "tileimageuri": "https://productimages.withfloats.com/tile/667d44a2576e8da931df856b.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-06-07T07:23:04.367Z", "updatedon": "2024-06-27T10:53:21.595Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/vildiabate-m-850-/1504", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "VILDIABATE M 850 ", "category": "DIABETIC RANGE", "tags": [ "vildagliptin metformin 50/850 price", "vildagliptin and metformin hydrochloride tablets s" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "6662b1e6870e7b20c49e6522", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "VILDIABATE M 500 ", "description": "VILDIABATE M 500 \nMetformin (500mg)SR, Vildagliptin (50mg)\nIntroduction to VILDIABATE M 500\nVILDIABATE M 500 is a combination medication designed to manage type 2 diabetes mellitus effectively. It contains Metformin Hydrochloride Sustained Release (SR) 500mg and Vildagliptin 50mg. This dual-action formula targets different pathways involved in glucose regulation to provide comprehensive blood sugar control. It is used alongside diet and exercise to improve glycemic control in adults with type 2 diabetes.\n\nKey Components and Their Mechanisms\nMetformin SR 500mg\nMetformin is a biguanide that helps lower blood sugar levels through several mechanisms:\n\nReduces Hepatic Glucose Production: Metformin decreases the amount of glucose produced by the liver.\nImproves Insulin Sensitivity: It enhances the sensitivity of muscle cells to insulin, promoting better glucose uptake and utilization.\nDecreases Intestinal Absorption of Glucose: Metformin reduces the absorption of glucose from the gastrointestinal tract.\nThe sustained-release (SR) formulation ensures a gradual release of the medication, providing prolonged therapeutic effects and reducing the risk of gastrointestinal side effects.\n\nVildagliptin 50mg\nVildagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that works by:\n\nEnhancing Incretin Levels: Vildagliptin inhibits the DPP-4 enzyme, which degrades incretin hormones such as GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic peptide). These hormones increase insulin secretion and decrease glucagon release in a glucose-dependent manner.\nImproving Postprandial Glucose Control: By enhancing the action of incretin hormones, Vildagliptin helps regulate blood sugar levels after meals.\nBenefits of VILDIABATE M 500\nComprehensive Blood Sugar Control\nFasting and Postprandial Glucose Management: The combination of Metformin SR and Vildagliptin effectively manages both fasting and postprandial (after-meal) blood sugar levels.\nImproved Insulin Sensitivity and Secretion: Metformin improves insulin sensitivity, while Vildagliptin enhances insulin secretion in response to meals.\nExtended Release Formulation\nProlonged Effect: The sustained-release formulation of Metformin ensures a steady release of the medication, providing long-lasting blood sugar control and minimizing peaks and troughs in blood sugar levels.\nReduced Gastrointestinal Side Effects: The gradual release of Metformin helps reduce common gastrointestinal side effects associated with immediate-release formulations.\nAdditional Health Benefits\nLow Risk of Hypoglycemia: Vildagliptin has a low risk of causing hypoglycemia (low blood sugar) because it enhances insulin secretion only when blood glucose levels are elevated.\nWeight Neutral: This combination is generally weight-neutral, making it a suitable option for patients concerned about weight gain.\nDosage and Administration\nRecommended Dosage\nDosage: The typical dosage is one tablet taken once or twice daily, preferably with a meal to reduce gastrointestinal side effects.\nAdministration: Swallow the tablet whole with a glass of water. Do not crush, chew, or split the tablet unless advised by your healthcare provider.\nGuidelines for Optimal Use\nConsistent Use: For best results, take VILDIABATE M 500 regularly at the same time each day as prescribed by your healthcare provider.\nMonitor Blood Sugar Levels: Regular monitoring of blood sugar levels is essential to ensure the medication is effectively controlling your diabetes. Adjustments to your treatment plan may be necessary based on these readings.\nFor further information: \nEMAIL: info@sterispharma.com / contact@sterispharma.com \n CALL/WHATSAPP: 7877551268, 7849827488 \n Order Now\nhttps://www.sterisonline.com/product/vildiabate-m-500-133454", "price": 289.0, "discountamount": 86.7, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 7, "_keywords": [ "GIP", "diet", "Order", "EMAIL", "water", "glass", "liver", "GLP-1", "peaks", "meals", "adults", "amount", "option", "troughs", "Fasting", "exercise", "Low Risk", "patients", "readings", "response", "Enhancing", "same time", "biguanide", "Guidelines", "one tablet", "weight gain", "Optimal Use", "information", "Adjustments", "utilization", "Vildagliptin", "Metformin SR", "sterispharma", "Hypoglycemia", "Introduction", "best results", "sterisonline", "DPP-4 enzyme", "muscle cells", "CALL/WHATSAPP", "glucose uptake", "steady release", "typical dosage", "Key Components", "treatment plan", "Weight Neutral", "Consistent Use", "Administration", "Incretin Levels", "gradual release", "low blood sugar", "glycemic control", "DPP-4) inhibitor", "VILDIABATE M 500", "glucagon release", "Prolonged Effect", "incretin hormones", "insulin secretion", "several mechanisms", "different pathways", "Regular monitoring", "glucose regulation", "dual-action formula", "Insulin Sensitivity", "healthcare provider", "blood glucose levels", "Intestinal Absorption", "combination medication", "gastrointestinal tract", "dipeptidyl peptidase-4", "type 2 diabetes mellitus", "glucose-dependent manner", "meal) blood sugar levels", "Recommended Dosage Dosage", "Additional Health Benefits", "Hepatic Glucose Production", "Extended Release Formulation", "sustained-release formulation", "prolonged therapeutic effects", "immediate-release formulations", "Postprandial Glucose Management", "long-lasting blood sugar control", "comprehensive blood sugar control", "sustained-release (SR) formulation", "common gastrointestinal side effects", "Reduced Gastrointestinal Side Effects", "Improving Postprandial Glucose Control", "glucose-dependent insulinotropic peptide", "Metformin Hydrochloride Sustained Release" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 1499, "imageuri": "https://productimages.withfloats.com/actual/667d4af8b567218985111efd.png", "tileimageuri": "https://productimages.withfloats.com/tile/667d4af8b567218985111efd.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-06-07T07:08:22.623Z", "updatedon": "2024-06-27T11:20:23.412Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/vildiabate-m-500-/1499", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "VILDIABATE M 500 ", "category": "DIABETIC RANGE", "tags": [ "vildagliptin metformin 50/1000", "vildagliptin metformin 50/500 price", "ildagliptin and metformin hydrochloride tablets si" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "6662af26db100e1fdc2dcc17", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "VILDIABATE M 1000 ", "description": "VILDIABATE M 1000 \nMetformin (1000mg)SR, Vildagliptin (50mg)\nIntroduction to VILDIABATE M 1000\nVILDIABATE M 1000 is a combination medication designed for the effective management of type 2 diabetes mellitus. It contains Metformin Hydrochloride Sustained Release (SR) 1000mg and Vildagliptin 50mg. This dual-action formula targets different pathways involved in glucose regulation to provide comprehensive blood sugar control. It is used alongside diet and exercise to improve glycemic control in adults with type 2 diabetes.\n\nKey Components and Their Mechanisms\nMetformin SR 1000mg\nMetformin is a biguanide that helps lower blood sugar levels through several mechanisms:\n\nReduces Hepatic Glucose Production: Metformin decreases the amount of glucose produced by the liver.\nImproves Insulin Sensitivity: It enhances the sensitivity of muscle cells to insulin, promoting better glucose uptake and utilization.\nDecreases Intestinal Absorption of Glucose: Metformin reduces the absorption of glucose from the gastrointestinal tract.\nThe sustained release (SR) formulation ensures a gradual release of the medication, providing prolonged therapeutic effects and reducing the risk of gastrointestinal side effects.\n\nVildagliptin 50mg\nVildagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that works by:\n\nEnhancing Incretin Levels: Vildagliptin inhibits the DPP-4 enzyme, which degrades incretin hormones such as GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic peptide). These hormones increase insulin secretion and decrease glucagon release in a glucose-dependent manner.\nImproving Postprandial Glucose Control: By enhancing the action of incretin hormones, Vildagliptin helps regulate blood sugar levels after meals.\nBenefits of VILDIABATE M 1000\nComprehensive Blood Sugar Control\nFasting and Postprandial Glucose Management: The combination of Metformin SR and Vildagliptin effectively manages both fasting and postprandial (after-meal) blood sugar levels.\nImproved Insulin Sensitivity and Secretion: Metformin improves insulin sensitivity, while Vildagliptin enhances insulin secretion in response to meals.\nExtended Release Formulation\nProlonged Effect: The sustained-release formulation of Metformin ensures a steady release of the medication, providing long-lasting blood sugar control and minimizing peaks and troughs in blood sugar levels.\nReduced Gastrointestinal Side Effects: The gradual release of Metformin helps reduce common gastrointestinal side effects associated with immediate-release formulations.\nAdditional Health Benefits\nLow Risk of Hypoglycemia: Vildagliptin, in particular, has a low risk of causing hypoglycemia (low blood sugar) because it enhances insulin secretion only when blood glucose levels are elevated.\nWeight Neutral: This combination is generally weight neutral, making it a suitable option for patients concerned about weight gain.\nDosage and Administration\nRecommended Dosage\nDosage: The typical dosage is one tablet taken once daily, preferably with a meal to reduce gastrointestinal side effects.\nAdministration: Swallow the tablet whole with a glass of water. Do not crush, chew, or split the tablet unless advised by your healthcare provider.\nGuidelines for Optimal Use\nConsistent Use: For best results, take VILDIABATE M 1000 regularly at the same time each day as prescribed by your healthcare provider.\nMonitor Blood Sugar Levels: Regular monitoring of blood sugar levels is essential to ensure the medication is effectively controlling your diabetes. Adjustments to your treatment plan may be necessary based on these readings.\nFor further information: \nEMAIL: info@sterispharma.com / contact@sterispharma.com \n CALL/WHATSAPP: 7877551268, 7849827488 \n Order Now\nhttps://www.sterisonline.com/product/vildiabate-m-1000-133453", "price": 319.0, "discountamount": 95.7, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 7, "_keywords": [ "GIP", "diet", "GLP-1", "Order", "EMAIL", "water", "glass", "liver", "peaks", "meals", "adults", "amount", "option", "troughs", "Fasting", "exercise", "Low Risk", "patients", "response", "readings", "same time", "Enhancing", "biguanide", "one tablet", "Guidelines", "Optimal Use", "information", "utilization", "weight gain", "Adjustments", "Introduction", "Vildagliptin", "Metformin SR", "VILDIABATE M", "sterispharma", "best results", "Hypoglycemia", "sterisonline", "DPP-4 enzyme", "muscle cells", "CALL/WHATSAPP", "Weight Neutral", "Consistent Use", "Administration", "treatment plan", "steady release", "typical dosage", "Key Components", "glucose uptake", "low blood sugar", "Incretin Levels", "gradual release", "SR) formulation", "glucagon release", "glycemic control", "Prolonged Effect", "DPP-4) inhibitor", "insulin secretion", "incretin hormones", "several mechanisms", "different pathways", "glucose regulation", "Regular monitoring", "dual-action formula", "healthcare provider", "Insulin Sensitivity", "blood glucose levels", "effective management", "Intestinal Absorption", "gastrointestinal tract", "combination medication", "dipeptidyl peptidase-4", "type 2 diabetes mellitus", "glucose-dependent manner", "meal) blood sugar levels", "Recommended Dosage Dosage", "Additional Health Benefits", "Hepatic Glucose Production", "Extended Release Formulation", "sustained-release formulation", "prolonged therapeutic effects", "immediate-release formulations", "Postprandial Glucose Management", "long-lasting blood sugar control", "comprehensive blood sugar control", "common gastrointestinal side effects", "Reduced Gastrointestinal Side Effects", "Improving Postprandial Glucose Control", "glucose-dependent insulinotropic peptide", "Metformin Hydrochloride Sustained Release" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 1496, "imageuri": "https://productimages.withfloats.com/actual/6662af29d878d473a9fda03d.png", "tileimageuri": "https://productimages.withfloats.com/tile/6662af29d878d473a9fda03d.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-06-07T06:56:38.67Z", "updatedon": "2024-06-28T11:39:06.99Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/vildiabate-m-1000-/1496", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "VILDIABATE M 1000 ", "category": "DIABETIC RANGE", "tags": [ "VILDIABATE M 1000", "Metformin (1000mg)SR", "Vildagliptin (50mg)", "Vildagliptin 50mg side effects", "Vildagliptin tablets 50 mg uses", "Vildagliptin 50 mg price", "Vildagliptin 50 mg and metformin 500 mg" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false } ], "hasmoreitems": false, "isapirequest": false, "totalresults": 27, "query": null, "floatingpoint": null }